Safety and Efficacy of Tumor Necrosis Factor Antagonists in Older Patients With Ulcerative Colitis: Patient-Level Pooled Analysis of Data From Randomized Trials

Shivashankar, 2017, Incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010, Clin Gastroenterol Hepatol, 15, 857, 10.1016/j.cgh.2016.10.039 Taleban, 2015, Inflammatory bowel disease and the elderly: a review, J Crohns Colitis, 9, 507, 10.1093/ecco-jcc/jjv059 Gisbert, 2014, Systematic review with meta-analysis: inflammatory bowel disease in the elderly, Aliment Pharmacol Ther, 39, 459, 10.1111/apt.12616 Ortman, 2014, An aging nation: the older population in the United States He W, Goodkind D, Kowal P. An aging world: 2015. U.S. Census Bureau, International Population Reports, P95/16-1, U.S. Government Publishing Office, Washington, DC, 2016. Sturm, 2017, European Crohn’s and Colitis Organisation topical review on IBD in the elderly, J Crohns Colitis, 11, 263 Shrestha, 2019, Management of ulcerative colitis in the elderly, Drugs Aging, 36, 13, 10.1007/s40266-018-0611-x Manosa, 2018, Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study, Aliment Pharmacol Ther, 47, 605, 10.1111/apt.14494 Ananthakrishnan, 2016, Systematic review and meta-analysis: phenotype and clinical outcomes of older-onset inflammatory bowel disease, J Crohns Colitis, 10, 1224, 10.1093/ecco-jcc/jjw054 Ananthakrishnan, 2009, Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations, Inflamm Bowel Dis, 15, 182, 10.1002/ibd.20628 Desai, 2013, Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease, Inflamm Bowel Dis, 19, 309, 10.1002/ibd.23026 Kumar, 2017, Elderly-onset and adult-onset ulcerative colitis are more similar than previously reported in a nationwide cohort, Dig Dis Sci, 62, 2857, 10.1007/s10620-017-4734-4 Cottone, 2011, Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease, Clin Gastroenterol Hepatol, 9, 30, 10.1016/j.cgh.2010.09.026 Lobaton, 2015, Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease, Aliment Pharmacol Ther, 42, 441, 10.1111/apt.13294 Toruner, 2008, Risk factors for opportunistic infections in patients with inflammatory bowel disease, Gastroenterology, 134, 929, 10.1053/j.gastro.2008.01.012 Krumholz, 2016, The Yale Open Data Access (YODA) project: a mechanism for data sharing, N Engl J Med, 375, 403, 10.1056/NEJMp1607342 Panaccione, 2014, Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis, Gastroenterology, 146, 392, 10.1053/j.gastro.2013.10.052 Rutgeerts, 2005, Infliximab for induction and maintenance therapy for ulcerative colitis, N Engl J Med, 353, 2462, 10.1056/NEJMoa050516 Sandborn, 2014, Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis, Gastroenterology, 146, 85, 10.1053/j.gastro.2013.05.048 Sandborn, 2014, Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis, Gastroenterology, 146, 96, 10.1053/j.gastro.2013.06.010 Charpentier, 2014, Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study, Gut, 63, 423, 10.1136/gutjnl-2012-303864 Lewis, 2008, Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis, Inflamm Bowel Dis, 14, 1660, 10.1002/ibd.20520 Simmonds, 2005, Meta-analysis of individual patient data from randomized trials: a review of methods used in practice, Clin Trials, 2, 209, 10.1191/1740774505cn087oa Cates, 2002, Simpson’s paradox and calculation of number needed to treat from meta-analysis, BMC Med Res Methodol, 2, 1, 10.1186/1471-2288-2-1 Team, 2018 Osterman, 2016, Crohn’s disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab, Am J Gastroenterol, 111, 1806, 10.1038/ajg.2016.433 Ha, 2012, Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population, Clin Gastroenterol Hepatol, 10, 1002, 10.1016/j.cgh.2012.02.004